Bruker Corporation (NASDAQ:BRKR) Given Average Rating of “Hold” by Brokerages

Bruker Corporation (NASDAQ:BRKR) has earned an average rating of “Hold” from the sixteen ratings firms that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $56.7857.

A number of research firms recently issued reports on BRKR. TD Cowen reissued a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. UBS Group set a $60.00 price objective on shares of Bruker in a research report on Wednesday, June 24th. Stifel Nicolaus set a $45.00 price objective on shares of Bruker in a report on Friday, May 8th. Finally, Citigroup boosted their price objective on shares of Bruker from $44.00 to $60.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th.

Institutional Trading of Bruker

A number of institutional investors have recently modified their holdings of BRKR. Orbis Allan Gray Ltd boosted its position in Bruker by 5.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after acquiring an additional 761,258 shares during the last quarter. State Street Corp raised its holdings in shares of Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after purchasing an additional 91,706 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Sculptor Capital LP lifted its position in shares of Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after purchasing an additional 270,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after purchasing an additional 2,289,269 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Performance

Bruker stock opened at $60.45 on Friday. The company’s 50-day moving average is $56.32 and its two-hundred day moving average is $46.32. Bruker has a 1 year low of $28.53 and a 1 year high of $64.54. The company has a market cap of $9.20 billion, a PE ratio of -251.88, a PEG ratio of 1.94 and a beta of 1.29. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts anticipate that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.